In this phase 3 trial, crinecerfont was superior to placebo in reducing elevated androstenedione levels and lowering glucocorticoid doses in pediatric participants with classic congenital adrenal hyperplasia.
The New England Journal of Medicine: Search Results in Pediatrics
